Engaged in R&D efforts to produce complex libraries of long DNA strands for the age of synthetic biology

Led a multidisciplinary project to develop an exosome-based vaccine starting from the initial proposal. Rationally designed libraries of antigen-displaying proteins. Designed and developed screening assays to identify lead candidates and managed collaborations with both in house teams and academic partners. Demonstrated the ability of exosomes to stabilize biochemically complex and problematic antigens, leading to outstanding in vivo potency.Group leader and scientific manager of 3 direct reports. Developed a custom high-throughput screening platform and applied it to evaluate rationally designed therapeutic proteins, accelerate lead product selection and screen upstream process variables - all with increased speed and reproducibility, while minimizing cost and FTE investment.

Engineering native pathways in producer cells to decorate extracellular vesicles with therapeutic transmembrane proteins, load extracellular vesicles with soluble therapeutic proteins, and separately load extracellular vesicles with small RNA therapeutics. Scientific manager of one direct report tasked with developing a high throughput screening platform for therapeutic transmembrane protein evaluation.

Invented, developed and patented a class of chimeric recombinant proteins that exploit native producer cell pathways to become enriched in exosomes. Covalently fusing therapeutic entities to these novel proteins permits indication-flexible biochemical modification of exosomes.

Used a cell-based, synchronous, inducible protein aggregation system to temporally resolve and identify the earliest responses of the cellular protein homeostasis network to acute protein misfolding.Used a genome-wide CRISPR-Cas9 screen to identify genes that influence the escape of soluble protein toxins from the endomembrane system into the cytosol.

Identified two C3H1 zinc binding sites required for assembling an active conformation in the catalytic site in a family of multi-pass transmembrane enzymes, called DHHC palmitoyl acyl-transferases.

Performed and evaluated bacterial growth kinetics in cultures supplemented with metabolic pathway intermediates to assess the potential for rational pathway engineering, with the goal of optimizing the fitness of commodity chemical production strains.Performed routine lab maintenance and support in a microbiology and metabolic engineering research lab.

Regulatory affairs certified (RAC) associate who worked with other team members to craft regulatory approval strategies, audit ongoing clinical trials, perform gap analyses of manufacturing documentation, and submit FDA filings on behalf of clients for several different biologic products under regulatory review.